AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30477552 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-enhancing physical activity (HEPA) support program
Number of subjects: 30
Study 28644575 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin plus bismuth‐based quadruple therapy (RBAL)
Number of subjects: 67
Study 28644575 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin‐based triple therapy (RAL)
Number of subjects: 67
Study 28644575 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 67
Study 26271275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 50
Study 26271275 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 50
Study 23984728 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 3 mg
Number of subjects: 742
Study 23984728 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 742
Study 23984728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 21390215 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a stick to touch the object
Number of subjects: 6
Study 21390215 — intervention group
Group type: COMPARATOR
Intervention: Using a hand to touch the object
Number of subjects: 6
Study 18326123 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐minute writing task
Number of subjects: 71
Study 16860698 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (efavirenz, EFV)
Number of subjects: 911
Study 16860698 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor (nelfinavir, NFV)
Number of subjects: 911
Study 16860698 — intervention group
Group type: COMPARATOR
Intervention: Both (EFV/NFV)
Number of subjects: 911
Study 12664518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg/kg
Number of subjects: 72
Study 12664518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg
Number of subjects: 72
Study 12664518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tramadol 0.5 mg/kg/6 hours for 24 hours
Number of subjects: 72
Study 12664518 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 children with one dose of Tramadol 2 mg/kg)
Number of subjects: 72
Study 10326070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis of trabecular bone texture on calcaneus radiographs
Number of subjects: 39
Study 10326070 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck bone mineral density (FNBMD)
Number of subjects: 39
Study 10326070 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric bone mineral density (TRBMD)
Number of subjects: 39
Study 10326070 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve for Hmean
Number of subjects: 39
Study 10326070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis in overlapping subgroups of FNBMD or TRBMD
Number of subjects: 39
Study 8948740 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis with cell saver
Number of subjects: 50
Study 8948740 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative autotransfusion
Number of subjects: 50
Study 2565999 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 32
Study 2565999 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 32
Study 1108694 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 20-25 ml of normal saline
Number of subjects: 150
Study 1108694 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 150
Study 1108694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 150
Study 7406657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate (single oral dose)
Number of subjects: 0
Study 31831801 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask without micro ventilator (MF)
Number of subjects: 106
Study 31831801 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask with micro ventilator (MF)
Number of subjects: 106
Study 31831801 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask with and without MF
Number of subjects: 106
Study 28343801 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF (Ready-to-Use Therapeutic Food)
Number of subjects: 68
Study 28343801 — intervention group
Group type: COMPARATOR
Intervention: ONS (Oral Nutritional Supplements)
Number of subjects: 68
Study 26273900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal
Number of subjects: 48
Study 26273900 — intervention group
Group type: COMPARATOR
Intervention: Ready-to-eat oat-based breakfast cereal (RTEC)
Number of subjects: 48
Study 25074698 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - inflation of a blood pressure cuff on the left thigh to 15 mm Hg above systolic for four 5‐minute intervals
Number of subjects: 299
Study 25074698 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulus (blinded)
Number of subjects: 299
Study 21883811 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (1 g 12-h)
Number of subjects: 49
Study 21883811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 18635696 — intervention group
Group type: EXPERIMENTAL
Intervention: SL65.1498 (three doses)
Number of subjects: 0
Study 18635696 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 0
Study 18635696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17244295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash and Counseling (treatment group)
Number of subjects: 0
Study 17244295 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly hired workers (treatment group)
Number of subjects: 0
Study 17244295 — intervention group
Group type: COMPARATOR
Intervention: Agency workers (control group)
Number of subjects: 0
Study 14704597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 12149661 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 22
Study 12149661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 22
Study 12149661 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 22
Study 9800063 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent replacement soft contact lenses
Number of subjects: 2
Study 9800063 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily wear soft contact lenses
Number of subjects: 2
Study 8556087 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thermodilution method
Number of subjects: 14
Study 8556087 — intervention group
Group type: COMPARATOR
Intervention: Intermittent thermodilution method
Number of subjects: 14
Study 2104790 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 10
Study 2104790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 400862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine combined with indomethacin
Number of subjects: 44
Study 400862 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine and placebo
Number of subjects: 44
Study 30824956 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL‐1401H
Number of subjects: 0
Study 30824956 — intervention group
Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 0
Study 28860266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 279
Study 25223369 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 50, 100, 250, 500 or 1000 mg twice daily
Number of subjects: 336
Study 25223369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 25223369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily
Number of subjects: 336
Study 25223369 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE)
Number of subjects: 336
Study 23356455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GP care and cognitive-behavioral intervention group (n = 54)
Number of subjects: 108
Study 23356455 — intervention group
Group type: COMPARATOR
Intervention: GP care control group (n = 54)
Number of subjects: 108
Study 21274703 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 79
Study 21274703 — intervention group
Group type: COMPARATOR
Intervention: No-stress condition
Number of subjects: 79
Study 19574102 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-minute audio relaxation program
Number of subjects: 41
Study 19574102 — intervention group
Group type: COMPARATOR
Intervention: 12-minute Mozart andante
Number of subjects: 41
Study 17084549 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice daily) with concurrent cisplatin (75 mg/m2) and 5-FU (1g/m2 for 4 days) and pelvic radiation therapy
Number of subjects: 84
Study 15159243 — intervention group
Group type: COMPARATOR
Intervention: T54 carriers
Number of subjects: 22
Study 15159243 — intervention group
Group type: COMPARATOR
Intervention: T54 carriers after olive oil
Number of subjects: 22
Study 15159243 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 22
Study 15159243 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 22
Study 15159243 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 22
Study 11237478 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (26% fatty acid as LCPUFA including 4.6% gamma-linolenic acid, 7.4% arachidonic acid, 5.5% eicosapentaenoic acid, 8% DHA)
Number of subjects: 20
Study 11237478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 20
Study 9876503 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone tablets
Number of subjects: 0
Study 9876503 — intervention group
Group type: COMPARATOR
Intervention: Dissolution parameters
Number of subjects: 0
Study 8011009 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-unit formulation (Diclo-Puren 50)
Number of subjects: 12
Study 8011009 — intervention group
Group type: COMPARATOR
Intervention: Single-unit formulation (reference)
Number of subjects: 12
Study 2575369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 2575369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/day
Number of subjects: 120
Study 2575369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/day
Number of subjects: 120
Study 2575369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/day and Cicletanine 100 mg/day
Number of subjects: 120
Study 1190365 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (2.5 g during 5 days to 7.5 g in 10 days for children; 5 g in 5 days or 12.5 g in 10 days for adults)
Number of subjects: 20
Study 29888663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment during pregnancy
Number of subjects: 150
Study 29888663 — intervention group
Group type: COMPARATOR
Intervention: Dental examination (non-treated group)
Number of subjects: 150
Study 29691569 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclosed formaldehyde cresol (FC) with CAVITON‐GC after removal of crown pulp
Number of subjects: 223
Study 29691569 — intervention group
Group type: COMPARATOR
Intervention: Open drainage
Number of subjects: 223
Study 26156651 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg per day)
Number of subjects: 795
Study 23774238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat (0.2 mg/kg/hour continuous intravenous infusion)
Number of subjects: 26
Study 23774238 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 26
Study 21114862 — intervention group
Group type: EXPERIMENTAL
Intervention: Free school breakfast programme (non-sugar coated breakfast cereal, milk products, and/or toast and spreads)
Number of subjects: 400
Study 21114862 — intervention group
Group type: EXPERIMENTAL
Intervention: Free school breakfast programme
Number of subjects: 400
Study 18809423 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted face cues in a visual cueing paradigm (Experiment 1)
Number of subjects: 0
Study 18809423 — intervention group
Group type: COMPARATOR
Intervention: Upright and inverted face cues (Experiment 2)
Number of subjects: 0
Study 18809423 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of predictiveness of cues (Experiment 3)
Number of subjects: 0
Study 18809423 — intervention group
Group type: COMPARATOR
Intervention: Replication of Experiment 2 with extended stimulus set (Experiment 4)
Number of subjects: 0
Study 16894407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid once-daily 200 mg tablets
Number of subjects: 26
Study 16894407 — intervention group
Group type: COMPARATOR
Intervention: Zytram 200 mg tablets
Number of subjects: 26
Study 12509627 — intervention group
Group type: EXPERIMENTAL
Intervention: Doloteffin (60 mg of harpagoside daily for 6 weeks)
Number of subjects: 88
Study 12509627 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib (12.5 mg/day for 6 weeks)
Number of subjects: 88
Study 10994324 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen
Number of subjects: 124
Study 10994324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid mouthwash
Number of subjects: 124
Study 10994324 — intervention group
Group type: COMPARATOR
Intervention: Mucosal flaps
Number of subjects: 124
Study 8706482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg administered intravenously)
Number of subjects: 50
Study 8706482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent administered intravenously)
Number of subjects: 50
Study 1714011 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN + NAC (600 mg q.i.d.)
Number of subjects: 7
Study 1714011 — intervention group
Group type: COMPARATOR
Intervention: ISDN + placebo
Number of subjects: 7
Study 1714011 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN + NAC
Number of subjects: 7
Study 6178382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline, 5 to 10 mg every or every other day
Number of subjects: 4
Study 6178382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30897012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nuts
Number of subjects: 54
Study 30897012 — intervention group
Group type: COMPARATOR
Intervention: Pretzels
Number of subjects: 54
Study 29543659 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive pain-coping strategy of guarding
Number of subjects: 384
Study 29543659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing appraisal measures
Number of subjects: 384
Study 29543659 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive responses (guarding, resting, pain catastrophizing)
Number of subjects: 384
Study 29543659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive responses
Number of subjects: 384
Study 29543659 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive responses
Number of subjects: 384
Study 28797611 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 50
Study 28797611 — intervention group
Group type: COMPARATOR
Intervention: Written instructions
Number of subjects: 50
Study 26037176 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home based exercise program
Number of subjects: 30
Study 26037176 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 23237575 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise for 8 weeks
Number of subjects: 17
Study 23237575 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counselling for 8 weeks
Number of subjects: 17
Study 23237575 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise and group counselling combined
Number of subjects: 17
Study 23237575 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counselling first followed by exercise
Number of subjects: 17
Study 23237575 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise first followed by group counselling
Number of subjects: 17
Study 20602503 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured bike and strengthening regimen (bike/strengthening group, 58 patients)
Number of subjects: 112
Study 20602503 — intervention group
Group type: COMPARATOR
Intervention: Simpler walking and breathing regimen (walk/breathing group, 54 patients)
Number of subjects: 112
Study 18238962 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive ring
Number of subjects: 500
Study 18238962 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive patch
Number of subjects: 500
Study 16603285 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella resurfacing (n=25)
Number of subjects: 50
Study 16603285 — intervention group
Group type: COMPARATOR
Intervention: No patella resurfacing (n=25)
Number of subjects: 50
Study 14660155 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with alcohol dependence and PTSD
Number of subjects: 84
Study 14660155 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with alcohol dependence and PTSD
Number of subjects: 84
Study 14660155 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 84
Study 10967698 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (sustained-release) 2.5 mg
Number of subjects: 100
Study 10967698 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 100
Study 8790198 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐VIP (150‐200 MBq; 1 microgram)
Number of subjects: 50
Study 8790198 — intervention group
Group type: COMPARATOR
Intervention: 111In‐CYT‐103 (150 MBq; 1 mg)
Number of subjects: 50
Study 8790198 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐VIP
Number of subjects: 50
Study 8790198 — intervention group
Group type: COMPARATOR
Intervention: 111In‐CYT‐103
Number of subjects: 50
Study 8218966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tenoxicam (20 mg)
Number of subjects: 24
Study 8218966 — intervention group
Group type: COMPARATOR
Intervention: Oral tenoxicam (20 mg)
Number of subjects: 24
Study 3799499 — intervention group
Group type: EXPERIMENTAL
Intervention: Paffenbarger survey
Number of subjects: 255
Study 3799499 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Paffenbarger
Number of subjects: 255
Study 3799499 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale integrated activity monitor (LSI)
Number of subjects: 255
Study 3799499 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake
Number of subjects: 255
Study 3799499 — intervention group
Group type: EXPERIMENTAL
Intervention: Baecke survey
Number of subjects: 255
Study 28628251 — intervention group
Group type: COMPARATOR
Intervention: Single-drug regimens (Vemurafenib, Dabrafenib, Nivolumab)
Number of subjects: 16
Study 28628251 — intervention group
Group type: COMPARATOR
Intervention: Double-drug regimens (Dabrafenib + Trametinib, Nivolumab + Ipilimumab, Vemurafenib + Cobimetinib)
Number of subjects: 16
Study 28628251 — intervention group
Group type: COMPARATOR
Intervention: Single-drug regimens (Vemurafenib, Dabrafenib)
Number of subjects: 16
Study 28628251 — intervention group
Group type: COMPARATOR
Intervention: Double-drug regimens (Dabrafenib + Trametinib, Vemurafenib + Cobimetinib)
Number of subjects: 16
Study 27368882 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy and breast surgery
Number of subjects: 431
Study 24274384 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater magnitude stimuli (number, size, color saturation)
Number of subjects: 0
Study 24274384 — intervention group
Group type: COMPARATOR
Intervention: Manipulations to the direction of the sequence
Number of subjects: 0
Study 24274384 — intervention group
Group type: COMPARATOR
Intervention: Ordered (continuous) or nonordered (discontinuous) pattern trajectories
Number of subjects: 0
Study 24673050 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation combined with artificial periodic therapy
Number of subjects: 65
Study 24673050 — intervention group
Group type: COMPARATOR
Intervention: Artificial periodic therapy with oral administration of medroxyprogesterone acetate tablets
Number of subjects: 65
Study 22467989 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature of 16°C
Number of subjects: 40
Study 22467989 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature of 20°C
Number of subjects: 40
Study 22467989 — intervention group
Group type: COMPARATOR
Intervention: Room temperature of 24°C
Number of subjects: 40
Study 20973708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin(®) LA 20 mg
Number of subjects: 147
Study 20973708 — intervention group
Group type: COMPARATOR
Intervention: Medikinet(®) Retard
Number of subjects: 147
Study 20973708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 17963813 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked primes with a target-congruent shape
Number of subjects: 0
Study 17963813 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked shape-incongruent primes
Number of subjects: 0
Study 17963813 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual rotation detection
Number of subjects: 0
Study 17963813 — intervention group
Group type: EXPERIMENTAL
Intervention: Shapes of masked stimuli
Number of subjects: 0
Study 15582637 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (weekly for 4 months)
Number of subjects: 94
Study 15582637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminiscence intervention)
Number of subjects: 94
Study 12397268 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte rehydration solution
Number of subjects: 168
Study 12397268 — intervention group
Group type: COMPARATOR
Intervention: Regular clear fluids
Number of subjects: 168
Study 10522131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (2.5‐3 micrograms/kg/min)
Number of subjects: 24
Study 10522131 — intervention group
Group type: COMPARATOR
Intervention: No dobutamine
Number of subjects: 24
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorder diagnosis
Number of subjects: 750
Study 8978228 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance misuse diagnosis
Number of subjects: 750